by @JTC_PALIdev | Aug 19, 2024 | Press Releases
Carlsbad, CA, Aug. 19, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with...
by @JTC_PALIdev | Aug 13, 2024 | Press Releases
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) before year end – Company continues to establish growing body of preclinical data for PALI-2108 and...
by @JTC_PALIdev | Aug 8, 2024 | Press Releases
– Phase 1 human clinical study of PALI-2108 for the treatment of Ulcerative Colitis (UC) on track to commence before year end – Based on the modeling and simulations, Palisade has established dose levels and trial design for PALI-2108 Carlsbad, CA, Aug....
by @JTC_PALIdev | Jul 31, 2024 | Press Releases
Mitch Jones, MD, PhD, CMO of Palisade Bio highlights recent findings from a microbiome study confirming local bioactivation of lead product candidate, PALI-2108 Carlsbad, CA, July 31, 2024 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a...
by @JTC_PALIdev | Jul 29, 2024 | Press Releases
Findings demonstrate that the microbiome and enzymes are sufficient in mouse, dog, and Normal Healthy Volunteers (NHV) and Ulcerative Colitis (UC) patients Company advancing toward commencement of Phase 1 human clinical study of PALI-2108 for the treatment of UC...
